Elena Marchetti spends her working life at the point where a prescription meets a real parasite, a real interaction, a real patient who has read something frightening online. Her instinct is to slow down and separate what a drug genuinely does from the story that has grown up around it — a habit that matters more with ivermectin than almost any drug of the last decade. Reader questions sent to Gravix Pharma get that same patient sorting of signal from noise.
She trained in infectious diseases in Italy and then took a subspecialty in clinical pharmacology and therapeutics, which is an unusual pairing and exactly the one Gravix needs: someone who can talk about a worm's nervous system and a cytochrome enzyme in the same breath. Much of her week is spent on an antimicrobial-stewardship committee, weighing whether a drug earns its place. She brings that same scrutiny to every Gravix page.
On the antiparasitics she is precise and unromantic. Ivermectin is a genuinely brilliant drug for the things it is meant for — river blindness, strongyloidiasis, scabies — and she says so without hedging. She is just as direct that the large, careful trials do not support it for COVID-19, and she will not soften that to please anyone. Mebendazole she treats as the quiet workhorse it is: a cheap, well-tolerated tablet that clears the common worm infections families actually meet.
With the erectile-dysfunction drugs she leads with the rule that keeps people out of the emergency department: tadalafil, sildenafil and vardenafil must never be combined with nitrates in any form, prescribed or recreational, because the stacked drop in blood pressure can be dangerous. She repeats it in nearly every thread, because it is the mistake that does the most harm.
She refuses to crown one PDE5 inhibitor the winner. In the trials the three land in the same efficacy band; the honest choice comes down to pharmacology and the shape of a person's life — tadalafil's long window, sildenafil's low cost and long record, vardenafil's place in between. She lays out onset, duration, the food effect and the QT caveat, then leaves the decision with the reader and their prescriber.
She cites things a reader can check — the FDA label, a WHO fact sheet, a named trial, MedlinePlus — because she thinks an answer nobody can verify is worth very little. Every reply ends on the same note: this is a doctor teaching in general, not a plan built for you. When the honest answer depends on your bloods, your other medicines or an examination she cannot do from a distance, she says so and points you back to your own clinician.
Last Updated